Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
The Californer/10247898

FOSTER CITY, Calif. ~ Gilead Sciences, Inc. has announced a new grant program in the United States called Gilead Relink, which is focused on bringing diagnosed but untreated people living with hepatitis C virus (HCV) or hepatitis B virus (HBV) back into care. The CDA Foundation (CDAF), based in Lafayette, Colorado, will act as the lead organization for the program and be responsible for implementing and overseeing Gilead Relink.

The grant program is part of Gilead's commitment to addressing the unmet needs of people living with viral hepatitis globally. According to the U.S. Department of Health and Human Services, an estimated 2.4 million people are living with HCV and 850,000 are estimated to be living with HBV in the United States alone. Both HCV and HBV are responsible for increasing rates of cirrhosis, liver cancer, liver failure and premature deaths.

Gilead Relink aims to identify and bridge the gaps that remain in linking people living with HCV and HBV back to necessary care and treatment by prioritizing three programmatic areas – utilizing evidence-based solutions, leveraging successful intervention and data collection models, and emphasizing knowledge sharing and convening. The grant program will provide a total of $8 million in funding through CDAF which will distribute funds to grantees identified by CDAF that meet certain criteria, integral strategic planning and technical assistance.

More on The Californer

• OGN INVESTIGATION NOTICE: Investigation Launched into Organon & Co. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm
• San Diego Author Debuts Thrilling Time-Travel Novel
• Bennett Awards Designs Two Cohesive Custom Awards for 2025 Sci-Tech Academy Awards
• Poll Finds Overwhelming Opposition to Keeping Big Cats as Pets
• SM Telecom Expands AT&T Partnership to Deliver Cutting-Edge 5G+ Wireless Solutions New Collab Brings AT&T's Advanced 5G+ Technology to Cellphone

Macky Natha, Vice President of Medical Affairs at Gilead Sciences said: "We are thrilled to expand our support to healthcare organizations through the new Gilead Relink grant program...As we work toward eliminating viral hepatitis as a public health threat by 2030, we must address barriers to treatment by relinking the people who have been lost in the process."

Homie Razavi, Founder and Managing Director at CDA Foundation added: "The relink grant funded by Gilead is an important example of how public and private partnerships can shape viral hepatitis elimination programs that will help the United States achieve the WHO elimination targets by 2030."

Gilead has been committed to improving lives of people living with liver disease for more than two decades through initiatives such as HepConnect which was launched in 2019 as a five-year multi-million dollar initiative aimed at expanding HCV screening, linking people to care, improving healthcare professional education and supporting evidence-based harm reduction services through partnerships.

---

Show All News | Report Violation